‘Trojan Horse’ particle sneaks chemotherapy in to kill ovarian cancer cells
12 September 2011
A common chemotherapy drug has been successfully delivered to cancer cells inside tiny microparticles using a method inspired by our knowledge of how the human immune system works. The drug, delivered in this way, reduced ovarian cancer tumours in an animal model by 65 times more than using the standard method. This approach is now being developed for clinical use.
Cancer cell (red and blue nucleus) that ingested two large microparticles (green)
Credit: Dr Davidson Ateh, BioMoti Limited
The research was funded by, among others, the Biotechnology and Biological Sciences Research Council (BBSRC) Follow-on Fund - funding for 'proof of concept' at the very early stage of turning research outputs into a commercial proposition - and carried out at Queen Mary, University of London. The study will be published next week in the journal, Biomaterials.
Dr Davidson Ateh, who worked on the research at Queen Mary, University of London and set up the start-up company, BioMoti, that will develop the technology for clinical use said "It's like we've made a re-enactment of the battle of Troy but on the tiniest scale. In Troy, the Greeks fooled the Trojans into accepting a hollow horse full of soldiers - we've managed to trick cancer cells into accepting drug-filled microparticles."
Dr Ateh and colleagues found that by coating tiny microparticles of around a hundredth the diameter of a human hair with a special protein called CD95, they could in fact trigger cancer cells into ingesting these particles. Not only that, but the particles could deliver a dose of a common chemotherapy drug called paclitaxel.
The key to their success is that CD95 attaches to another protein called CD95L, which is found much more commonly on the surface of cancer cells than it is on normal healthy cells. Once attached, the cancer cells ingest CD95 and the microparticle with it.
Inside the cell, the microparticle can unload its chemotherapy cargo, which kills the cell to reduce the size of the tumour.
Dr Ateh added "Other researchers had already noticed that cancer cells may use this CD95-CD95L arrangement to avoid being destroyed by the immune system, which is why they display more CD95L than normal cells. We've managed to turn this to our advantage and hijack the cancer cell's own trick-of-the-trade to get our 'Trojan Horse' through the gate."
Co-author and Professor of Gynaecological Oncology at Queen Mary, University of London, Iain McNeish commented "Chemotherapy is still the main way that we treat ovarian cancer, which can be particularly aggressive and difficult to treat. Anything we can do to concentrate the treatment in tumour cells and at the same time protect healthy cells is a good thing. This is an elegant method and if it works in a clinical setting as well as we hope it will patients could experience a better treatment with fewer side effects."
Principal investigator and Professor of Pathology at Queen Mary, University of London, Joanne Martin added "There are lots of drugs that we would like to deliver into cells - not just chemotherapies - and this could work for those too. For example, there are new classes of drugs to treat tumours, such as biological therapies. If we could load biological therapies into the same CD95-coated particles, then there's no reason why they couldn't also be delivered in this way."
The researchers are now advancing these studies and BioMoti is seeking to attract larger and established pharmaceutical companies to partner the technology, dubbed OncoJanTM in reference to the earlier Trojan horse, for the clinical development of new treatments in specific types of cancer.
Professor Douglas Kell, Chief Executive, BBSRC said "BBSRC funds a great deal of work that is aimed at improving our fundamental understanding of biological processes. When there are opportunities to use this understanding to the benefit of people, it is vitally important to seize and make the most of them. This is a good example where research into the human immune system has led to a new technology that has the potential to underpin health and wellbeing into later life."
Notes to editors
This research is discussed in the following journal paper, which is available online here: www.sciencedirect.com/science/article/pii/S014296121100843X.
Ateh DD, et al.. The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials 2011;32(33):8538-8547.
About Queen Mary, University of London
Queen Mary, University of London is one of the UK's leading research-focused higher education institutions with some 16,000 undergraduate and postgraduate students.
Amongst the largest of the colleges of the University of London, Queen Mary's 3,000 staff deliver world-class degree programmes and research across three faculties: Science and Engineering; Humanities and Social Sciences and the School of Medicine and Dentistry.
One of the rising stars in UK higher education, Queen Mary was ranked 11th nationally in the last Research Assessment Exercise, and was rated as one of the world's elite universities in the 2010 Times Higher Education's Top 200 World University Rankings (120th place).
The College has a strong international reputation with around 23% of students coming from over 130 countries.
Queen Mary has an annual turnover of £300M, research income worth £70M, and a yearly impact on the UK economy of over £750M.
Queen Mary, as a member of the 1994 Group of research-focused universities, has made a strategic commitment to the highest quality of research, but also to the best possible educational, cultural and social experience for its students. The College is unique among London's universities in being able to offer a completely integrated residential campus, with a 2,000-bed award-winning Student Village on its Mile End campus. For more information see: www.qmul.ac.uk.
BioMoti Limited is a privately held UK based company engaged in the development of platform drug delivery technologies. In particular, BioMoti focuses on improving the delivery of active agents to the intracellular space. This is achieved by packaging the drug compounds into functionalised microparticles designed to access the interior of targeted biological cells. BioMoti is currently focussed on improving the delivery of drugs in cancer; helping to increase efficacy and reduce toxicity. Paired with the appropriate pharmaceutical agents, BioMoti technology can form a substantial portion of the worldwide market in the treatment of specific cancers by offering opportunities to target new intracellular mechanisms, reformulate compounds and contribute to the patent extension of marketed drugs. The total oncology market was worth over $50Bn in 2009 and strong double-digit growth is expected due to increased demand from an ageing population predominantly affected by cancer and the on-going need for innovative medicines. For more information see: www.biomoti.com. Contact: email@example.com.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by Government, and with an annual budget of around £445M, we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
Matt Goode, Head of External Relations
tel: 01793 413299